Search

everythinglearnresearchcommunity

for

Search:↓

The combination therapy improved PCOS symptoms in both obese and non-obese women, with weight loss in the obese group.

Adalimumab significantly improved symptoms and quality of life in two patients with Hidradenitis Suppurativa.

OBEME effectively enhances wound healing and could be a promising carrier for skin treatments.

Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.

Tofacitinib is effective for treating alopecia areata, and starting treatment early may improve results.

Boron neutron capture therapy for head and neck cancer can cause side effects like mouth sores and skin irritation, which vary depending on where the treatment is aimed.

Afatinib often causes skin problems that need proactive management.

Irradiating the whole central nervous system can lead to over 50% of patients with cerebellar medulloblastoma surviving three years.

Finasteride may help treat childhood brain tumors by activating certain genes.

DOPE:DOPC liposomes can improve targeted cancer drug delivery, reducing side effects and increasing effectiveness.

Intralesional steroids are more effective for hair regrowth in alopecia areata than NBUVB, but combining them doesn't improve results.

Using a niacinamide cream can improve life quality for breast cancer patients during chemotherapy.

Raltitrexed conjugates are less potent than the free drug but more effective at high concentrations.

Removing lymph nodes does not improve survival for advanced ovarian cancer and may cause more complications.

Removing the ovarian tumor improved the woman's hormonal symptoms.

Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.

Removing a methyl group from the ITGAV gene speeds up bone formation in a specific type of bone disease model.

IMTA can help regrow hair in severe alopecia areata when JAK inhibitors don't work well.

Enhanced stem cells from the placenta can reduce fat cell formation in eye disease.

Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.

Baricitinib is effective in promoting hair growth in severe alopecia areata.

Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.

Budesonide is not effective for maintaining remission in Crohn's disease beyond three months.

CTP-543 is generally safe for treating alopecia areata.

A combination of ixekizumab and tofacitinib successfully treated severe scalp cellulitis, leading to hair regrowth.

Ixekizumab is safe for long-term use with low rates of major heart-related events.

BIVV009 is a safe treatment for bullous pemphigoid that reduces C3 deposition without harmful side effects.

Noggin promotes skin tumors by activating Wnt and Shh pathways.